Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics

Intellia Therapeutics

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today

uniQure

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives

Shares of Editas Medicine, a genome editing company that utilizes CRISPR technology, soared as much as 50% to new all-time highs on Monday. There was no official news from the company to explain the move higher. The move does follow a Friday interview conducted by Bloomberg with ARK Invest founder Cathie Wood, who explained that she sees genomic stocks driving the bulk of the gains for her flagship fund over the next five years.

Editas surges 50% as ARK founder Cathie Wood sees genomic stocks driving returns for the next 5 years (EDIT)

Editas Medicine (EDIT) stock is soaring higher on Monday with heavy trading despite a lack of recent news from the gene-editing company. The post Editas Medicine: 6 Things for Potential EDIT Stock Investors to Know Today appeared first on InvestorPlace.

Editas Medicine: 6 Things for Potential EDIT Stock Investors to Know Today

Here are some best guesses about the biotech stock's huge jump.

Why Editas Medicine Stock Is Skyrocketing Today

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors.

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

Sangamo Therapeutics

Vertex Pharmaceuticals

In the Century of Biology, it pays to own the future of curing disease at the root.

CRISPR Gene Editing: Owning the Future of Medicine

Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.

Editas (EDIT) Submits Application to Start Study on EDIT-301

The biotech just filed to advance its second pipeline candidate into clinical testing.

Why Editas Medicine Stock Is Skyrocketing for the Fourth Day in a Row

Editas Medicine saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96. The post Editas Medicine Receives IBD Stock Rating Upgrade appeared first on Investor's Business Daily.

Editas Medicine Receives IBD Stock Rating Upgrade

EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease

Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA

Momentum continues from the biotech's weekend presentation of promising data for its experimental sickle cell disease therapy.

Why Editas Medicine Stock Is Rising for a Third Consecutive Day

Momentum continued from the biotech's positive update announced over the weekend.

Why Editas Medicine Stock Jumped Again Today

Biogen

BioNTech SE

Eli Lilly

Novo Nordisk

Roche Holding AG

Sanofi

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

How You Can Profit From the Best-Managed Drugmaker on Earth

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?

Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies

Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Editas has foundational expertise in CRISPR technology. It has recently entered clinical trials using its platform in a rare eye disease.

Editas Medicine: Plagued By Uncertainty, Awed By The Potential

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D. In connection with Dr. Michaels' appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Dr. Michaels as inducements material to Dr. Michaels entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of $30.41 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Michaels' employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Michaels' continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Dr. Michaels' employment start date until the fourth anniversary of Dr. Michaels' employment start date, subject to Dr. Michaels' continued service to Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company's Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michaels will lead clinical research and drug development for the Company's pipeline of experimental medicines.

Editas Medicine Appoints Lisa A. Michaels, M.D.

Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.

Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus

Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2020 Results - Earnings Call Transcript

Editas (EDIT) delivered earnings and revenue surprises of 118.18% and 759.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Tops Q3 Earnings and Revenue Estimates

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2020.

Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

Editas Medicine to Participate in Upcoming Investor Conference

CAMBRIDGE,  Mass., Sept.  11, 2020  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle Charpentier (CVC) and the Broad Institute, Inc. (Broad) regarding certain Broad CRISPR/Cas9 patents Editas Medicine exclusively licenses. The USPTO granted Broad’s motion for priority benefit while denying CVC priority benefit to its two earliest provisional patent applications. As a result, Broad will enter the priority phase of the interference as “Senior Party” while CVC remains the “Junior Party” for purposes of determining which entity was the first to invent the inventions at issue.

News for Editas Medicine Stock (EDIT)